The Odyssey Group International Sports Advisory Board Including Three Super Bowl MVPs will Appear on “Banfield”  to Discuss Concussion Treatments

Irvine, California, UNITED STATES


IRVINE, CA, July 27, 2021 (GLOBE NEWSWIRE) --  Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, medical products including a treatment for concussion, today announced members of  its management team and Sports Advisory Board will appear on “Banfield” with Ashleigh Banfield. 

Odyssey Group International Appearance on “Banfield”
Date: Tuesday, July 27, 2021
Time: 10:00 pm ET
Channel: NewsNation, https://www.newsnationnow.com

VP of Drug Development, Jake VanLandingham, along with members of its Sports Advisory Board (SAB), including NFL legends Brett Favre, Kurt Warner and Mark Rypien will discuss the need for a treatment for concussion and provide an overview of the Company’s drug candidate PRV-002, a novel neurosteroid being developed for the treatment of concussion. The SAB supports Odyssey’s outreach efforts to enhance public awareness of concussion as well as the need for an FDA approved therapy. It is estimated that 15% of individuals that sustain a concussion develop long term health deficiencies. Last month the Murdoch Children's Research Institute (MCRI) published in the British Journal of Sports Medicine that 1/3 of youth who sustain a concussion develop a mental health issue. 

Award-winning veteran journalist Ashleigh Banfield is the host of “Banfield” on NewsNation airing weeknights at 10:00pm ET. During her 30-year career, Banfield has served as host of the A+E prime-time series, “Live Rescue,” host of “Primetime Justice with Ashleigh Banfield” on HLN, anchored “Legal View with Ashleigh Banfield on CNN, and and co-anchored the CNN morning news show, “Early Start.” She has also served as a correspondent for ABC News, reporting for “Good Morning America,” “20/20,” “ABC World News Tonight,” and “Nightline.” As a correspondent for NBC News, Banfield reported for “The Today Show,” “NBC Nightly News,” and “Dateline.” During this time, she also anchored several prime-time series on MSNBC, including “A Region in Conflict and Ashleigh Banfield: On Location.

About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.

 

Contact Data